ALLARITY THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7911 USD | +4.92% |
|
-20.89% | -92.82% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 4.237 | 2.512 | 0.2444 | - | - |
| Enterprise Value (EV) 1 | 4.237 | 2.512 | 0.2444 | 0.2444 | 0.2444 |
| P/E ratio | -0.13 x | -0.05 x | -0.3 x | -0.51 x | -0.45 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 0.52 | 228 | 308.9 | - | - |
| Reference price 2 | 8,226 | 11.02 | 0.7911 | 0.7911 | 0.7911 |
| Announcement Date | 3/13/23 | 3/8/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.118 | - | - | - | - | - | - | - |
| EBITDA | -9.806 | -9.31 | - | - | - | - | - | - |
| EBIT 1 | -21.84 | -9.47 | - | -32.68 | -17.13 | -23.61 | -29.06 | -32.78 |
| Operating Margin | -18,513.02% | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -25.79 | -9.326 | - | -17.58 | -11.82 | -16.44 | -28.84 | -32.51 |
| Net income 1 | -20.36 | -7.527 | -26.65 | -21.05 | -20.42 | -16.44 | -28.84 | -32.51 |
| Net margin | -17,262.76% | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | -61,880 | -205.2 | -2.600 | -1.560 | -1.740 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/20 | 3/31/21 | 5/17/22 | 3/13/23 | 3/8/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.302 | -4.329 | -4.562 | -4.97 | -3.659 | -4.156 | -4.426 | -4.879 | -4.937 | -5.924 | -6.22 | -6.531 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -4.307 | -4.653 | -5.032 | -3.141 | -3.352 | -2.38 | -4.447 | -1.639 | -3.159 | -3.097 | -5.188 | -4.997 |
| Net income 1 | -4.652 | -4.657 | -6.683 | -3.102 | -3.356 | -9.786 | -5.552 | -1.722 | -3.159 | -3.097 | -5.188 | -4.997 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -15,680 | -14,560 | -19,040 | -6,440 | -3,544 | -525.6 | -44.80 | - | -1.760 | -0.2900 | -0.2800 | -0.2700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/27/22 | 8/22/22 | 11/14/22 | 3/13/23 | 5/11/23 | 8/14/23 | 11/14/23 | 3/8/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | 1.25 | - | - | - | - | - | - |
| Net Cash position | 0.97 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.1347 x | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.01 | 0 | - | - | - | - | - | - |
| Capex / Sales | 7% | - | - | - | - | - | - | - |
| Announcement Date | 3/31/20 | 3/31/21 | 5/17/22 | 3/13/23 | 3/8/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.7911
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -92.82% | 244K | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ALLR Stock
- Financials Allarity Therapeutics, Inc.